Ghrelin-Mimicking Drug Boosts Brain Cell Growth but Fails to Prevent Alzheimer's Damage in Mice | Research

The takeaway

The ghrelin mimetic MK0677 promoted new brain cell growth in Alzheimer's model mice but could not prevent amyloid plaques, brain inflammation, synapse loss, or cognitive decline — and increased mortality at higher doses.

Failed to prevent any Alzheimer's pathology despite improved neurogenesis
MK0677 increased new neuron formation but could not stop amyloid deposition, synaptic loss, inflammation, or cognitive decline in 5xFAD mice, and increased mortality at 3 mg/kg

What the researchers found

MK0677, a potent ghrelin mimetic that activates the growth hormone secretagogue receptor (GHSR1α), improved hippocampal neurogenesis in 5xFAD Alzheimer's model mice when given at the asymptomatic stage. However, it failed to prevent amyloid-β deposition, synaptic loss, microglial activation, or cognitive impairment. At a dose of 3 mg/kg, MK0677 significantly increased mortality in these mice. Despite promoting new neuron formation, ghrelin receptor activation alone was insufficient to protect against Alzheimer's pathology.

Why it matters

This is an important negative result. Ghrelin and its receptor had been proposed as potential therapeutic targets for Alzheimer's disease based on their role in promoting synaptic function and neurogenesis. This study, combined with a previously failed large-scale clinical trial, demonstrates that MK0677 alone is not effective for AD prevention or treatment. This redirects the field away from a promising but ultimately unsuccessful approach and saves resources that might have been spent on further development of this strategy.

The numbers in context

3 mg/kg dose increased mortality · Improved neurogenesis · No prevention of Aβ deposition · No synaptic protection · No cognitive benefit · Failed large-scale clinical trial cited

How the study worked

Preclinical study using 5xFAD transgenic mice (a model of AD-like amyloidosis) treated with MK0677 beginning at the asymptomatic stage. Researchers assessed hippocampal neurogenesis, amyloid-β deposition, synaptic integrity, microglial activation, cognitive function (behavioral testing), and survival across treatment groups.

Who was studied

5xFAD transgenic Alzheimer's model mice treated with MK0677 ghrelin mimetic starting at the asymptomatic stage

What this study cannot tell us

The 5xFAD model produces aggressive amyloid pathology that may be more severe than typical human AD progression, potentially overwhelming any protective effects. The study tested only one ghrelin mimetic (MK0677) and did not test actual ghrelin peptide or combination therapies. The mechanism behind increased mortality at 3 mg/kg was not fully explored.

How to read the evidence

This is a preclinical animal study using a well-characterized Alzheimer's mouse model. The negative result is significant because it aligns with a failed large-scale human clinical trial, strengthening the conclusion that MK0677 alone is ineffective for AD. The consistency between animal and human negative results increases confidence in this conclusion.

When this study was published

Published in 2019, this study contributed to closing the chapter on MK0677 as a standalone Alzheimer's therapy. The referenced failed clinical trial and this preclinical data together provide strong evidence against this approach.

The bigger picture

The ghrelin/GHSR1α pathway was an attractive therapeutic target for Alzheimer's disease because of its role in promoting neurogenesis and synaptic function. This study, along with the failed clinical trial, is part of a broader pattern of Alzheimer's research where interventions that seem promising in early preclinical work fail to translate into meaningful disease modification. It underscores that neurogenesis alone — while beneficial — cannot overcome the destructive cascade of amyloid-β toxicity, and suggests that multi-target approaches may be necessary.

Questions still open

Could MK0677 be effective when combined with anti-amyloid therapies rather than used alone?
Why does MK0677 increase mortality at 3 mg/kg in AD mice — is this related to metabolic effects, growth hormone elevation, or another mechanism?
Would other ghrelin receptor agonists or actual ghrelin peptide show different results than this small-molecule mimetic?

Common questions

What is MK0677 (ibutamoren) and how does it relate to ghrelin?

MK0677 (also known as ibutamoren) is a synthetic compound that mimics the action of ghrelin, the body's hunger hormone, by activating the same receptor (GHSR1α). This triggers growth hormone release and was hypothesized to promote brain health by enhancing neurogenesis and synaptic function. Unlike ghrelin itself (which is a peptide), MK0677 is a small molecule that can be taken orally.

If MK0677 promoted new brain cell growth, why didn't it help with Alzheimer's?

Alzheimer's disease involves a cascade of destructive processes — amyloid plaque buildup, inflammation, and loss of synaptic connections — that overwhelm the brain's capacity for repair. While new neurons were formed, they could not survive or function properly in the toxic environment created by amyloid-β. This demonstrates that simply making more neurons isn't enough if the underlying disease process continues unchecked.

Read the original research

MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology.

Journal of Alzheimer's disease : JAD, 72(2), 467-478

View on PubMed ↗Publisher’s paper ↗

Citation

Tian, Jing; Wang, Tienju; Wang, Qi; Guo, Lan; Du, Heng. (2019). MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology.. Journal of Alzheimer's disease : JAD, 72(2), 467-478. https://doi.org/10.3233/JAD-190779